Ascletis Pharma, Inc.HKEX: 1672

Voluntary announcement - ascletis announces FDA ind submission of ASC39, an oral small molecule selective amylin receptor agonist for the treatment of obesity

Oct 25, 2026 at 8:00 PM EDT · Issued by Ascletis Pharma, Inc. via HKEXnews

Filed with HKEX · Stock code 1672 · Oct 25, 2026 at 8:00 PM EDT

On 6ix: 6ix.com/news/voluntary-announcement-ascletis-announces-fda-ind-submission-of-asc39-an-oral-small-molecule-selective-amylin-receptor-agonist-for-the-treatment-of-obesity

View Attachment

6ix is reading this filing.

View original source (HKEXnews)Ascletis Pharma, Inc. on 6ix

Earlier from Ascletis Pharma

Later from Ascletis Pharma

Voluntary announcement - ascletis' oral small molecule glp-1, ASC30, demonstrated placebo-adjusted HBA1C reduction of 1.7% at 12 weeks from its U.S. phase ii study in participants with diabetesOct 28

All Ascletis Pharma news releases

Follow Ascletis Pharma into a list and get an email when it puts out news.

Follow Ascletis Pharma